Fda’s Policy Statement for the Development of New Stereoisomeric Drugs
ثبت نشده
چکیده
منابع مشابه
FDA's policy statement for the development of new stereoisomeric drugs.
Stereoisomers are molecules that are identical in atomic constitution and bonding, but differ in the three-dimensional arrangement of the atoms. For the purpose of this document, the stereoisomeric pairs of greatest interest are those with one or more asymmetric (chiral) centers whose enantiomers (individual stereoisomers) are mirror images. They have essentially identical physical (except for ...
متن کاملTrouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters
Background For the purpose of understanding the Food and Drug Administration’s (FDA’s) concerns regarding online promotion of prescription drugs advertised directly to consumers, this study examines notices of violations (NOVs) and warning letters issued by the FDA to pharmaceutical manufacturers. Methods The FDA’s warning letters and NOVs, which were issued to pharmaceutical companies over a...
متن کامل1 a Clinical Trial for the Food and Drug Administration ’ S Clinical Trial Process
The FDA is tasked with opposing goals which demand tradeoffs — the time and cost of clinical trials to assure safety and efficacy while also encouraging speedy drug advances and affordability. On top of that, there is no feedback mechanism to inform the FDA of the effectiveness of their tradeoff decisions. Dual Tracking is a proposed public policy field experiment that would provide needed feed...
متن کاملPediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
Introduction........................................................................................ 740 I. Pediatric Testing: A Historical Perspective of the “Therapeutic Orphan” ............................................................. 746 A. Past Attempts to Acquire Pediatric Labeling.................... 746 B. FDAMA Section 111—Pediatric Exclusivity...................... 749 C. FDA’s Ma...
متن کاملQuantum of Effectiveness Evidence in FDA’s Approval of Orphan Drugs Cataloguing FDA’s Flexibility in Regulating Therapies for Persons with Rare Disorders
One of the key underlying issues facing the development of all drugs, and particularly orphan drugs, is what kind of evidence the Food and Drug Administration (FDA) requires for approval. The Federal Food, Drug, and Cosmetic [FD&C] Act provides that for FDA to grant approval for a new drug, there must be “substantial evidence” of effectiveness derived from “adequate and well-controlled investig...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2001